Back to mobile site

PAVmed raises $45 million, eliminates convertible securities overhang

February 4, 2026 8:04 AM EST

PAVmed Inc. (NASDAQ: PAVM) completed preferred stock and senior secured note financings totaling $45 million in gross proceeds, using the funds to eliminate all previously outstanding convertible securities.

The medical technology company issued $30 million of Series D Convertible Preferred Stock with associated warrants exercisable for up to an additional $30 million upon publication of a positive Medicare local coverage determination for its EsoGuard test. The company also issued a $15 million senior secured note with a February 2029 maturity.

PAVmed used $22.3 million in cash and the $15 million note to redeem all outstanding Series C Convertible Preferred Stock and retire convertible debt. The transactions yielded approximately $7.7 million in net cash proceeds for working capital.

The Series D Preferred Stock conversion into common stock requires stockholder approval at a special meeting scheduled no later than April 30, 2026. The conversion price is set at $6.50 per share. PAVmed has secured voting agreements from stockholders representing approximately 25% of outstanding common stock supporting the conversion.

If warrants are exercised and preferred stock converts upon shareholder approval, the financings would add approximately $37.7 million in cash to the balance sheet and create a capital structure consisting entirely of common stock and long-term debt.

PAVmed operates in medical devices, diagnostics, and digital health sectors through subsidiaries including Lucid Diagnostics Inc. (NASDAQ: LUCD) and Veris Health Inc. The company holds 31 million shares of Lucid common stock on its balance sheet.

The financing was conducted by existing long-term investors, according to the company's press release statement.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Related Entities

Maynard Um, Mark Zuckerberg, ARK